Yentreve ........??? Incontinence drug launched in UK

[Guest guest]

" Yentreve (duloxetine), works by strengthening the muscle that

controls urine flow from the bladder.............. "

" Professor Cardozo, King's College Hospital London

It works by increasing the stimulation of the pudendal nerve which

strengthens the urethral sphincter at the opening of the bladder,

reducing urine leakage. ............... "

http://news.bbc.co.uk/1/hi/health/3644862.stm

Having a baby can trigger stress incontinence

Incontinence drug launched in UK

Having a baby can trigger stress incontinence

The first drug which can be used to treat stress urinary

incontinence has been licensed for use in the UK.

Yentreve (duloxetine), works by strengthening the muscle that

controls urine flow from the bladder.

Around four million UK women are thought to be affected by the

condition, which can be caused by childbirth, obesity or

constipation.

They are currently advised to do pelvic floor exercises to control

their condition, or to undergo surgery.

Many women affected by the condition avoid situations where they

could be embarrassed, such as not going to places if they do not

know where the toilet is.

A quarter of women affected by stress urinary incontinence are under

30.

Embarrassment

Yentreve, made by the pharmaceutical company Eli Lily, is a

serotonin and noradrenaline reuptake inhibitor.

It's a great achievement to have something we can give to these

women

Professor Cardozo, King's College Hospital London

It works by increasing the stimulation of the pudendal nerve which

strengthens the urethral sphincter at the opening of the bladder,

reducing urine leakage.

It has been licensed for women with moderate to severe symptoms,

which include accidental leakage during physical exertion, or

activities including coughing, sneezing, lifting or exercise.

Trials of the drug showed women taking it saw a 50% reduction in the

number of episodes of stress incontinence they experienced. Women

taking a dummy pill saw a reduction of a third.

Those taking the drug also reported significant improvements in

their quality of life, saying it had reduced the social

embarrassment of their condition and meant they no longer had to

avoid or limit what they did because of it.

Cardozo, professor of urogynaecology at King's College

Hospital London, told BBC News Online the drug would make a

difference to women.

" It will improve the quality of their lives. "

She added: " This is the first drug specifically for stress

incontinence. It's a great achievement to have something we can give

to these women. "

Professor Cardozo said incontinence was less of a taboo subject than

it used to be, but women were still embarrassed to talk about it.

[Guest guest]

" Yentreve (duloxetine), works by strengthening the muscle that

controls urine flow from the bladder.............. "

" Professor Cardozo, King's College Hospital London

It works by increasing the stimulation of the pudendal nerve which

strengthens the urethral sphincter at the opening of the bladder,

reducing urine leakage. ............... "

http://news.bbc.co.uk/1/hi/health/3644862.stm

Having a baby can trigger stress incontinence

Incontinence drug launched in UK

Having a baby can trigger stress incontinence

The first drug which can be used to treat stress urinary

incontinence has been licensed for use in the UK.

Yentreve (duloxetine), works by strengthening the muscle that

controls urine flow from the bladder.

Around four million UK women are thought to be affected by the

condition, which can be caused by childbirth, obesity or

constipation.

They are currently advised to do pelvic floor exercises to control

their condition, or to undergo surgery.

Many women affected by the condition avoid situations where they

could be embarrassed, such as not going to places if they do not

know where the toilet is.

A quarter of women affected by stress urinary incontinence are under

30.

Embarrassment

Yentreve, made by the pharmaceutical company Eli Lily, is a

serotonin and noradrenaline reuptake inhibitor.

It's a great achievement to have something we can give to these

women

Professor Cardozo, King's College Hospital London

It works by increasing the stimulation of the pudendal nerve which

strengthens the urethral sphincter at the opening of the bladder,

reducing urine leakage.

It has been licensed for women with moderate to severe symptoms,

which include accidental leakage during physical exertion, or

activities including coughing, sneezing, lifting or exercise.

Trials of the drug showed women taking it saw a 50% reduction in the

number of episodes of stress incontinence they experienced. Women

taking a dummy pill saw a reduction of a third.

Those taking the drug also reported significant improvements in

their quality of life, saying it had reduced the social

embarrassment of their condition and meant they no longer had to

avoid or limit what they did because of it.

Cardozo, professor of urogynaecology at King's College

Hospital London, told BBC News Online the drug would make a

difference to women.

" It will improve the quality of their lives. "

She added: " This is the first drug specifically for stress

incontinence. It's a great achievement to have something we can give

to these women. "

Professor Cardozo said incontinence was less of a taboo subject than

it used to be, but women were still embarrassed to talk about it.